514 related articles for article (PubMed ID: 21885487)
1. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
2. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
Blom M; Kievit W; Fransen J; Kuper IH; den Broeder AA; De Gendt CM; Jansen TL; Brus HL; van de Laar MA; van Riel PL
J Rheumatol; 2009 Oct; 36(10):2171-7. PubMed ID: 19723902
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
6. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
7. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
[TBL] [Abstract][Full Text] [Related]
8. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.
Chatzidionysiou K; van Vollenhoven RF
Scand J Rheumatol; 2013; 42(3):190-5. PubMed ID: 23286833
[TBL] [Abstract][Full Text] [Related]
9. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
12. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128
[TBL] [Abstract][Full Text] [Related]
13. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
[TBL] [Abstract][Full Text] [Related]
16. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
Karlsson JA; Kristensen LE; Kapetanovic MC; Gülfe A; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):507-13. PubMed ID: 18304941
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
18. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
19. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug.
Söderlin MK; Petersson IF; Geborek P
Scand J Rheumatol; 2012 Feb; 41(1):1-9. PubMed ID: 22118371
[TBL] [Abstract][Full Text] [Related]
20. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice.
Smith N; Ding T; Butt S; Gadsby K; Deighton C
Rheumatology (Oxford); 2008 Sep; 47(9):1389-91. PubMed ID: 18603597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
